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ABSTRACT 
 
Malaria continues to cause significant morbidity and mortality in several settings in the tropical regions of the world 
despite the availability of efficacious and potent antimalarial drugs. This has led to an increased interest in and 
evaluation of micronutrients which are well known to have antioxidant effects. However, the interaction of 
micronutrients with malaria is not well characterized and there are conflicting results on their impact. This review 
examines, in particular, the relationship between vitamin supplements and malaria treatment. Data indicate that 
concurrent use of vitamins with antimalarial drugs may either accelerate the potency of the drugs or antagonize their 
effects. Also, evidence do exist that deficiencies of some of these supplements may protect, exacerbate or have both 
effects on malaria parasitemia, depending on the settings. Therefore, it is safe to speculate that the use of 
antimalarial drugs alongside vitamins should be approached with caution, in order to not undermine the potency of 
the drug and to assure effective disease treatment. 
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Introduction 
Malaria is a vector – borne, hemolytic disease of 
importance to global health caused by five species of 
the protozoan Plasmodium.Four of these – P. 
falciparum, P. vivax, P. malariae and P. ovale – are 
human malaria species that are spread from one person 
to another via the bite of female mosquitoes of the 
genus Anopheles. P. knowlesi malaria occurs in people 
when an Anopheles mosquito infected by a monkey 
then bites and infects humans [1]. Both P. falciparum 
and P. vivax malaria pose the greatest public health 
challenge; P. falciparum is most prevalent on the 
African continent, and is responsible for most deaths 
from malaria while P. vivax has a wider geographical 
distribution than P. falciparum [2], and can develop in 
the Anopheles mosquito vector at lower temperatures, 
and can survive at higher altitudes and in cooler 
climates. 
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*Correspondence  
Dr.Joshua B. Owolabi 
All Saints University College of Medicine, Kingstown, 
St. Vincent & the Grenadines 
E-Mail:joshua.owolabi@allsaintsu.org 
 
In many areas outside Africa, infections due to P. vivax 
are more common than those due to P. falciparum, and 
cause substantial morbidity [3].Infection by all 
Plasmodium spp. following the bite of an infected 
female Anopheles mosquito starts with a silent phase, 
primarily in the liver hepatocyte, then exoerythrocytic 
merozoite forms are passed into the blood stream as 
membrane-bound merosomes that rupture, allowing 
parasites access to circulating erythrocytes [4]. The 
merozoites rapidly invade erythrocytes, and as they 
grow and replicate, the intracellular parasite 
dramatically remodels the host red blood cell, giving 
rise to a rigid and poorly deformable cell with a 
propensity to adhere to a variety of cell types. These 
changes play a pivotal role in severe complications of 
P. falciparum malaria, with symptoms including fever, 
severe anemia, acute renal failure, hepatopathy, 
pulmonary edema, lactic acidosis, and in severe cases 
leading to coma and untimely death [5]. This review 
provides an overview of malaria epidemiology, 
prevention, diagnosis, treatment, and concludes with a 
discussion of vitamins that have been most intensively 
evaluated in relationship to malaria. 
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Epidemiology 
 
According to figures from the WHO [1], worldwide 
more than 200 million people develop malaria every 
year; most cases in Africa (88%), followed by South 
East Asia (10%) and the Middle East(2%). In 2015, 
around 438,000 patients died from the tropical disease, 
90% of them in Africa, in most cases children under 
five. Although, an increasing number of countries are 
moving towards eliminating malaria, zero indigenous 
cases have been reported from Europe [1]. 
Population groups at considerably higher risk of 
contracting malaria, and developing severe disease 
include infants, children under 5 years of age, pregnant 
women, malnourished people and patients with 
HIV/AIDS [1]. There is increasing evidence that P. 
falciparum malaria is influenced by ABO blood 
groupsystem;blood group A has been reported as a risk 
factor for severe malaria [6], and as a co-receptor for P. 
falciparumrosetting [7], whereas blood group O may 
offer some protection against severity of disease 
through the mechanism of reduced rosetting [8].In 
addition, there is evidence indicating that both the risk 
of acquiring P. falciparum infection, and the risk of 
developing severe complications are determined by 
host genetic factors [9]. The protective role of several 
erythrocytic variants, some of them related to blood 
groups, is one of the best examples of this genetic 
modulation [10]. The others include haemoglobins S, C 
and E, α and β thalassaemias, Glucose-6-phosphate 
dehydrogenase deficiency, Southern Asian 
Ovalocytosis, and Glycophorins A, B and C variants, 
all of which influence malaria pathogenesis [11]. 
 
Prevention 
 
Malaria disease has been associated with poverty and 
poor environmental conditions. The countries with high 
numbers of malaria cases have lower gross national 
incomes and lower total domestic government 
spending per capita than do countries with fewer cases 
[1]. Transmission of the disease can be reduced by 
vector control using insecticide-treated mosquito nets 
and indoor residual spraying dependent on the use of 
pyrethroids, however, in recent years, mosquito 
resistance to pyrethroids has emerged in many 
countries [12, 13]. Antimalarial medicines can also be 
used to prevent malaria; the WHO recommends 
intermittent preventive treatment with sulfadoxine-
pyrimethamine, at each scheduled antenatal visit after 
the first trimester in pregnant women, and 3 doses of 
intermittent preventive treatment with sulfadoxine- 
 
pyrimethamine for infants living in high-transmission 
areas of Africa [1]. 
 
Diagnosis 
 
Early and accurate diagnosis of malaria is essential for 
both rapid and effective disease management and 
malaria surveillance. Definitive diagnosis of the 
tropical disease depends on identification of the 
parasite in Giemsa-stained blood smears. Although, 
both thick and thin smears should be evaluated, thick 
smears are more sensitive for the detection of the 
parasite but are not useful for species identification. 
The newer rapid diagnostic tests (RDTs) that utilize 
monoclonal antibodies, which recognize the histidine-
rich protein or parasite lactate dehydrogenase, are 
easier to perform than blood smears and have 
sensitivities of 90–95% when compared to blood 
smears although they tend to be relatively insensitive if 
parasite density is low (e.g. < 500/ mcL) [14]. The 
levels of malaria diagnostic testing, in sub-Sahara 
Africa, which ranged from 36% of suspected malaria 
cases tested in 2005, to 41% in 2010 and 65% in 2014 
is primarily due to an increase in the use of RDTs [1]. 
However, in most rural clinics lacking the laboratory 
facilities to perform blood smears and without access 
to RDTs, the decision to treat for malaria is usually 
based on clinical findings. In high malaria risk areas 
any child with fever or a history of fever in the absence 
of signs of severe malaria is presumed to have 
uncomplicated malaria. 
 
Malaria is one of the major causes of child and 
maternal deaths [15], with serious consequences on the 
population, social and economic development of the 
countries where the disease is endemic. More than 80% 
of estimated malaria cases and deaths occur in fewer 
than 20 countries. In 2015, it is estimated that 15 
countries accounted for 80% of cases, and 15 countries 
accounted for 78% of deaths. The global burden of 
mortality is dominated by countries in sub-Saharan 
Africa, with the Democratic Republic of the Congo and 
Nigeria together accounting for more than 35% of the 
global total of estimated malaria deaths [1].  
 
Treatment 
 
There is currently no vaccine to provide any level of 
protection against malaria. However, a series of 
malaria chemoprophylaxis, based on the parasite’s life 
cycle and on the site of action, exists for use by 
travelers and immigrants to malaria endemic regions or 
countries [16]. These are blood stage prophylaxis such  
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as Mefloquine, Chloroquine, Amodiaquine which have 
to be continued for one month after leaving the malaria 
endemic area, and liver stage prophylaxis, drugs which 
act on the malaria parasites within the hepatocytes such 
as Primaquine and Malarone which can be 
discontinued a few days after leaving the endemic area. 
However, only Primaquine potentially may prevent all 
types of malaria including the late infection [16]. 
Treatment of malaria can be effected by the use of a 
variety of antimalarial drugs which are readily 
available and can be purchased over the counter. 
Although the proportion of children in sub-Saharan 
Africa with P. falciparum malaria receiving 
Artemisinin-based combination Therapies (ACT) as 
recommended by WHO [17], is estimated to have 
increased since 2000, access to treatment remains poor 
because a high proportion of children with fever are not 
taken for care or use the informal private sector, where 
they are less likely to obtain ACTs for treatment [1].  
 
Chloroquine, the mainstay of chemotherapy for several 
years in the management of parasitemia, has become 
obsolete in countries plagued with Chloroquine 
resistance by Plasmodium falciparum [18], with the 
exception of the following endemic regions; North 
Africa, the Middle East (though cases have been 
reported in some countries in this region), Haiti, 
Dominican Republic, Mexico, Central America, and 
Panama [19, 20]  where it is still the first line 
antimalarial drug used to treat uncomplicated or mild 
cases of malaria. 
In regions where Chloroquine resistance had 
developed, their first line anti-malaria drug was 
changed from chloroquine to Fansidar 
(pyrimethamine/sulfadoxine). However, Fansidar has 
been confronted with resistance in South America, 
much of Southeast Asia, other parts of Asia, and in 
large parts of Africa [21, 22]. In addition, resistance to 
Mefloquine has been reported in Thailand, some parts 
of Africa, South America, Middle East and Oceania 
[23]. However, despite sporadic clinical resistance to 
Quinine therapy in Southeast Asia and western Oceania 
but less frequent in South America and Africa, Quinine 
is still the preferred first line option in the treatment of 
severe malarial infection [1].  
 
With the alarming rate of resistance being posed by 
Plasmodium falciparum, other antimalarial drugs that 
have been formulated and recommended for use 
include Halofantrine, Tetracycline, Clindamycin and 
Doxycycline [24-26]. Chloroquine is still a valid  
 
choice for all P. vivax and P. ovale malaria infections 
except for P. vivax infections acquired in Papua New 
Guinea or Indonesia due to high prevalence of 
Chloroquine-resistance in those two countries. Rare 
cases of Chloroquine-resistant P. vivax have also been 
documented in Burma (Myanmar), India, and Central 
and South America [27]. 
 
ACTs are currently relied upon as first-line therapy for 
effective malaria treatment in most regions of the 
world in which the disease is endemic since they are 
effective, less toxic and well tolerated [28, 29], and 
their continuing efficacy is crucial if control and 
elimination programs are to succeed. The loss of 
effectiveness of artemisinin and its derivatives to drug 
resistance would constitute a major disaster in the fight 
against malaria. Resistance to artemisinins, however, 
has been confirmed in Cambodia, the Lao People’s 
Democratic Republic, Myanmar, Thailand and Viet 
Nam. In the large majority of sites, patients with 
artemisinin-resistant parasites still recover after 
treatment, provided that they are treated with an ACT 
containing an effective partner drug. However, along 
the Cambodia-Thailand border, P. falciparum has 
become resistant to almost all available antimalarial 
medicines [30, 31]. Artemisinin resistance in this 
Greater Mekong sub-region has occurred as a 
consequence of several factors including poor 
treatment practices, inadequate patient adherence to 
prescribed antimalarial regimens, and the widespread 
availability of oral artemisinin-based monotherapies 
and substandard forms of the drug. 
 
 
Interactions between Specific Micronutrients and 
Malaria 
 
Adequate intakes of micronutrients (vitamins and trace 
elements) are required for the immune system to 
function efficiently [32]. There is a growing body of 
evidence linking micronutrient deficiencies and malaria 
incidence arising mostly from P. falciparum endemic 
areas; malaria itself has been associated with 
malnutrition [33] and possibly micronutrient 
deficiencies [34, 35], and certain deficiencies may 
predispose to malaria incidence [36-38]. The following 
section provides an overview of a limited number of 
vitamins that have been most intensively evaluated in 
relationship to malaria. 
 
Vitamin A 
 
Vitamin A is an essential nutrient required for 
maintaining immune function, playing an important 
role in the regulation of cell-mediated immunity and in 
humoral antibody responses, suggesting that it could 
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play a role in protection against malaria [39]. It has 
been suggested that vitamin A deficiency impairs 
antibody response to malarial antigens that require 
Th2-mediated help [40]. In an investigation conducted 
by Serghides and Kain [41] on the effects of 9-cis-
retinoic acid, a metabolite of vitamin A, on CD36 
expression, non-opsonic phagocytic clearance of 
parasitized erythrocytes and TNFα production in 
human monocytes and macrophages, it was reported 
that the metabolite reduced secretion of TNFα, 
upregulated CD36 expression, and increased 
phagocytosis of Plasmodium falciparum-parasitized 
erythrocytes. The authors concluded that increased 
parasite clearance and reduced pro-inflammatory 
cytokine responses to infection might partly explain the 
beneficial effects of supplementation with vitamin A in 
malaria.  
 
A number of clinical studies have evaluated the impact 
of vitamin A supplementation on malaria, however, the 
outcomes are equivocal. Beneficial protective effects of 
vitamin A on malaria-related morbidity in young 
children have been demonstrated in Papua New Guinea 
and Zanzibari [42, 43]. However, two randomized, 
placebo-controlled trials conducted in Ghana did not 
find an overall significant effect of vitamin A on 
malaria parasitemia rates or parasite densities although 
the studies showed a reduction of 23% and 32% of 
probable malaria illness in supplemented children [44]. 
It should be noted that the number of children with 
probable malaria was so small that this study lacked 
adequate power to demonstrate an effect of vitamin A 
on slide-confirmed malaria morbidity. Similarly, in a 
randomized trial to examine the relationship of vitamin 
A supplementation with malaria incidence in HIV-
infected women, the following were the findings: 
Vitamin A supplementation compared with no vitamin 
A did not significantly alter the risk of developing 
clinical malaria [relative risk (RR) 0.97, 95% CI: 0.82 
to 1.14] nor the risk of malaria parasitemia (RR 1.02, 
95% CI: 0.84 to 1.24) [45].  
However, in a recent randomized controlled trial 
conducted in Burkina Faso [46] assessing the impact of 
a single dose of 200,000 IU of vitamin A with daily 
zinc supplementation for a period of six months on 148 
children aged 6–72 months, children in the 
supplemented group had a significant 30% reduction in 
slide confirmed malaria fevers [46]. On the other hand, 
the study by Mwanga and others [47] draws attention 
to the potential role of Vitamin A as adjunct therapy 
for cerebral malaria. The investigators studied 142 
children aged 6 months to 5 years, who were 
randomized to receive either Vitamin A or placebo and 
antimalarial treatment with intravenous Quinine. The 
results show that whereas there were no significant 
differences in outcome measures between the two 
treatment arms, there was a trend towards earlier 
resolution of convulsions and lower mortality (8.1%) in 
children who received Vitamin A supplementation 
compared to 16.2% in the placebo, although this 
difference in mortality did not reach statistical 
significance.   
 
Although, there is a lack of evidence suggesting that 
vitamin A is equal to or superior to well-established 
drug therapies used for the prevention or treatment of 
malaria, the available evidence suggests that vitamin A 
supplementation is a good strategy for children living 
in malaria endemic regions, because vitamin 
Adeficiency is common. Vitamin A supplementation 
reduces the incidence of uncomplicated malaria by 
about one-third in children, however, it does not appear 
to reduce significantly the rate of deaths that can be 
specifically attributed to severe malaria.  
 
Vitamin B Family 
 
B vitamins are reputed for their role as part of 
coenzymes in several metabolic pathways that 
participate in the release of energy from the energy 
nutrients (thiamin, riboflavin, niacin, pantothenic acid, 
and biotin), cell multiplication (folate and vitamin B12) 
and the body’s use of amino acid to synthesize protein 
(Vitamin B6). Co-administration of B complex with 
antimalarial medications appears to stem from the 
notion that vitamin B complex may improve appetite 
during the course of malaria therapy [48]. 
 
A recent report from Thailand suggests that deficiency 
of thiamine (vitamin B1) is associated with greater risk 
of severe malaria and with simple clinical malaria [49]. 
This is consistent with earlier reports that acute 
cerebral ataxia following malaria can be treated with 
thiamine [50], suggesting that disrupted thiamine 
metabolism may be a pathologic feature of malaria. In 
another research direction, the possibility of 
manipulating the metabolism of Vitamin B1 and B6 
has been suggested [51, 52], since it was observed that 
their biosynthesis pathways are essential for the P. 
falciparum parasite but absent in the human host. 
 
The influence Riboflavin (vitamin B2) on malaria 
morbidity appears to be one of antagonism such that 
deficiency confers a degree of protection. In Papua 
New Guinea, riboflavin-deficient infants are less likely 
to be infected with malaria [53]. Similar observations 
were made in India where a study reported less severe 
malaria parasitemia in Riboflavin-deficient persons 
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[54], although the course of clinical illness appeared 
worse. Because Riboflavin is an essential factor for 
glutathione peroxidase, an antioxidative enzyme, it has 
been proposed that deficiency promotes an oxidative 
environment that leads to destruction of the parasite. 
Indeed, reduced glutathione peroxidase activity has 
been observed in red cells from Riboflavin-deficient 
infected persons [55]. However, reduced glutathione 
peroxidase activity persisted in some population 
infected by the malaria parasite despite adequate 
riboflavin intake [56], suggesting that isoforms with 
reduced activity confer resistance to malaria. 
Paradoxically, P. falciparum–infected erythrocytes 
have an increased requirement for Riboflavin resulting 
in significant decrease in the average size of the food 
vacuole and inhibition of asexual parasite growth in 
culture [57]. Thus, although low Riboflavin status may 
be protective, high-dose Riboflavin therapy may prove 
beneficial for malaria patients suggesting that the 
protective and exacerbative functions would be based 
on different sites of action for the same antioxidant 
properties of Riboflavin [58]. In a recent study, 
Riboflavin combination with selected antimalarial 
drugs did not alter the potency of the drugs [59]. 
Folate, a crucial nutrient for cellular growth, important 
for erythrocyte production and prevention of neural 
tube defects, is part of prenatal care programs in most 
countries [60]. Given that Folate metabolism of the 
Plasmodium parasite is also a target for several 
antimalarial drugs including pyrimethamine, proguanil 
and dapsone [61] the interactions between host Folate 
status and supplementation in malaria-endemic areas 
has been of interest. Low malaria infection rates have 
been reported in pregnant women consuming a diet 
high in Folates [62], and greater infection rates were 
also reported in those suffering from megaloblastic 
anemia [63]. However, studies have clearly 
demonstrated that the addition of folate derivatives 
(folic acid or folinic acid) decreases the activity of 
antifolate drugs [64, 65]. Likewise, the lowering of 
Folate concentration in in vitro culture medium 
enhances the activity of antifolate antimalarial agents 
[66]. These reports suggest that Folic acid 
supplementation should be withheld during and for few 
days after antifolate drug administration.  
 
Vitamin C 
 
Vitamin C (Ascorbic Acid) is a water soluble vitamin 
that acts as an antioxidant, especially protecting the 
immune system cells from free radicals generated 
during their assault on invaders [67].It has, therefore, 
been suggested that vitamin C supplementation may 
have a role in case management of malaria [68]. 
Indeed, the plasma concentration of this antioxidant 
has been reported to be significantly decreased in 
chronic and acute malaria infections [69, 70].  
 
Investigations on synergistic antimalarial effect of 
some ketones and vitamin C have been equivocal. In an 
earlier study, vitamin C was reported to augment the 
antimalarial effects of a ketone, exofone, against P. 
falciparumin vitro, with a possible pro-oxidant activity 
(71). But contrary to these findings, poor synergism 
(5%) against P. berghei in mice was observed between 
certain ketones and vitamin C at a dose of 80 mg/kg 
body weight each [72]. The authors concluded that the 
lower doses of the ketones used in the combined 
therapy may be the reason for the observed poor 
synergism. In another study, combined administration 
of the vitamin with Chloroquine at a dose of 25 mg/kg 
body weight each, restored oxidative stress in female 
P. berghei-infected mice [73]. 
In a recent study that evaluated the effect of ascorbic 
acid on the efficacy of artemether against Plasmodium 
berghei-infected mice, it was shown that ascorbic acid, 
in high dose, significantly antagonized the anti-
plasmodial potency of artemether [74]. The average 
percent suppression in parasetemia was found to be 
51.4+/-32.21 as against that observed for artemether 
alone at 60.3+/-18.70. High dose of ascorbic acid may 
also suppress parasite growth. Although ascorbic acid 
/artemether interaction remains to be reported in large 
scale clinical trials, it is notable that a study 
investigating orange fruit juice (a source of vitamin C) 
combination with selected antimalarial drugs truncated 
the efficacy and potency of these drugs in malaria 
patients [59].Therefore, it is advisable to exclude 
vitamin C and its supplement from malarial therapy 
throughout the course of malaria treatment, to 
accelerate the efficacy and potency of the antimalarial 
agents. 
 
Vitamin D 
 
Vitamin D, a fat soluble vitamin that improves 
intestinal absorption of calcium, is either taken in 
dietary form or synthesized in the skin when expose to 
sunlight. An abnormal calcium-parathyroid hormone 
(PTH)-vitamin D axis has been reported as a cause of 
hypocalcemia in severe falciparum malaria without 
acute renal failure [75]. Mean calcium levels are 
significantly lower in complicated malaria when 
compared to uncomplicated malaria. Also, in acute 
falciparum malaria, mild hypocalcemia is common and 
simultaneously associated with inappropriately low 
serum PTH [76]. A role for vitamin D in malaria has 
been suggested by many studies [77]. Supporting a 
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beneficial anti-inflammatory role of vitamin D in 
malaria, a recent study reported that among mice 
infected with Plasmodium berghei malaria, those that 
received oral supplementation with vitamin D did not 
develop experimental cerebral malaria [78]. The 
authors suggested mechanistic explanation for this 
finding that vitamin D significantly reduced circulating 
levels of tumor necrosis factor–alpha (TNF-α), 
interferon-gamma ((IFN-γ), and interleukin-6 (IL-6), 
increasing concentrations of interleukin-10 (IL-10) and 
regulatory T cells, and was associated with lower levels 
of cyto-adherence molecules and better integrity of the 
blood-brain barrier.  
In a study in Uganda, Cusick and others [79] measured 
25-hydroxyvitamin D [25(OH)D] by immunoassay in a 
sample of children aged 18 months–12 years with 
severe malaria (cerebral malaria or severe malarial 
anemia, n=540) and in healthy community children 
(n=520). Ninety-five percent of children with severe 
malaria (n=538) and 80% of control children (n=516) 
were vitamin D insufficient (plasma 25(OH)D, 30 
ng/mL). Mean plasma 25(OH)D levels were 
significantly lower in children with severe malaria than 
in community children (21.2 vs. 25.3 ng/mL). Logistic 
regression revealed that for every 1 ng/mL increase in 
plasma 25(OH)D, the odds of having severe malaria 
declined by 9% [OR 50.91 (95% CI: 0.84, 1.0)]. The 
results suggest that vitamin D insufficiency may play a 
role in the development of severe malaria. This is 
consistent with the study reported by Madden and 
others [80] that indicate critically ill children 
demonstrated low levels of vitamin D. Further 
prospective studies in larger cohorts are indicated to 
confirm the relationship of vitamin D levels to severity 
of malaria infection and to investigate causality.  
 
Vitamin E 
 
Another potent antioxidant is vitamin E (α-
Tocopherol). Evidence from animal studies suggests 
that Vitamin E deficiency enhanced the antimalarial 
action of Qinghaosu (Artemisinin) against Plasmodium 
yoelii, both in terms of decreased parasitemia and 
improved survival [81]. Vitamin E may have a role in 
the development and clinical course of acute malaria in 
human. In a  Vietnamese study assessing the 
association between vitamin E and the clinical course 
of severe malaria, from 24 Vietnamese patients, aged 
18-62 years, receiving intensive treatment for 
complicated Plasmodium falciparum infections, serum 
vitamin E concentration was depressed at presentation 
relative to control subjects (7.6 +/- 5.6 versus 19.3 +/- 
4.7 µmol/l, respectively; P>0.001), and a subsequent 
rise to a level comparable with that of the control 
subjects after 4 days of treatment (but tended to be 
higher than the control value at the time of discharge (P 
>0.05); there was a significant correlation between 
admission ratio and parasite clearance time (P = 0.04) 
[82]. These findings are consistent with previous 
reports from animal models [81] and Chinese patients 
with falciparum malaria [83]. Thus, co-administration 
of malarial drugs and vitamin E has far reaching 
adverse consequences in controlling malarial infection 
[84]. Hence, the concurrent use of vitamin E and/or its 
supplement and antimalarial agents should be 
discouraged, to enhance the potency of the antimalarial 
medications to effectively treat malarial parasitemia. 
 
Summary & Conclusion 
 
Malaria remains a major public health problem in 
African, South East Asian, and the Mid-Eastern 
countries, despite the progress in reducing malaria 
cases and deaths, and possible elimination in dozens of 
countries, especially in the European region.  Several 
antimalarial drugs can be effectively used to manage 
the infection, however, there are challenges of 
resistance to contend with. Malaria itself has been 
associated with malnutrition and possibly micronutrient 
deficiencies and certain deficiencies may predispose to 
malaria incidence. There appears to be a role for the 
use of certain micronutrients, especially vitamin A and 
zinc, thiamine, and vitamin D for the prevention of 
malaria in children living in malaria endemic regions. 
Vitamin A supplementation reduces the incidence of 
uncomplicated malaria by about one-third in children, 
however, it does not appear to reduce significantly the 
rate of deaths that can be specifically attributed to 
severe malaria. It is thought that disrupted thiamine  
 
metabolism may be a pathologic feature of malaria and 
acute cerebral ataxia following malaria can be treated 
with thiamine. Limited studies support a beneficial 
anti-inflammatory role of vitamin D in preventing 
cerebral malaria. Riboflavin combination with selected 
antimalarial drugs do not alter their potency,  however, 
while low riboflavin status may be protective, high-
dose riboflavin therapy may prove beneficial for 
malaria patients suggesting that the protective and 
exacerbative functions would be based on different 
sites of action for the same antioxidant properties of 
this micronutrient. However, other essential vitamins 
such as vitamin C, vitamin E or folic acid may play 
potentially harmful roles by exacerbating malaria 
episodes or interfering with antimalarial therapy. 
Investigations on synergistic antimalarial effect of 
some ketones and vitamin C have been equivocal, and 
studies are emerging suggesting possible antagonism 
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by vitamin C of the potency of several antimalarial 
drugs, Artemether included. Therefore, it is advisable 
to exclude vitamin C and its supplement from malarial 
therapy throughout the course of malaria treatment, to 
accelerate the efficacy and potency of the antimalarial 
agents. Although, Folate uptake, remains a crucial   
part of prenatal care programs in most countries, 
studies have clearly demonstrated that the addition of 
folate derivatives (folic acid or folinic acid) decreases 
the activity of anti-folate drugs. Thus, folic acid 
supplementation should be withheld during and for few 
days after anti-folate drug administration. 
In conclusion, augmentation of malaria prevention 
and/or treatment with vitamins to enhance the 
nutritional status of young children and/or pregnant 
women in malaria-endemic areas requires caution, due 
to the fact that some of these nutrients are beneficial 
while others aggravate the disease state by slowing 
down the potency of these antimalarial drugs. This 
does not completely exclude the use of vitamins when 
managing malaria crisis, but it is safe to know the 
action of a particular supplement and the appropriate 
time to introduce it into the treatment regimen. Data on 
some other vitamins were limited and scarce to 
incorporate into this work. Therefore, it is 
recommended that further studies be done to clarify the 
role of other vitamins in the manipulation of malaria 
parasitemia. 
 
References 
 
1. World Health Organization (WHO). World 
Malaria Report 2015. 18 July 2016.  
http://www.who.int/malaria/visual-refresh/en/ (15 
August 2016). 
2. Prajapati SK, Joshi H, Shalini S, Patarroyo MA, 
Suwanarusk R, Kumar A, Sharma SK, Eapen A, 
Dev V, Bhatt RM, Valecha N, Nosten F, Rizvi 
MA and Dash AP. Plasmodium vivax lineages: 
Geographical distribution, tandem repeat 
polymorphism, and phylogenetic relationship. 
Malar J 2011; 10: 374. doi: 10.1186/1475-2875-
10-374 
3. Kochar DK, Das A, Kochar SK, Saxena V, Sirohi 
P, Garg S, Kochar A, Khatri MP and Gupta V. 
Severe Plasmodium vivax malaria: A report on 
serial cases from Bikaner in northwestern India. 
Am J Trop Med Hyg 2009; 80:194-98. 
4. Prudêncio M, Mota MM and Mendes AM. A 
toolbox to study liver stage malaria. Trends 
Parasitol 2011; 27: 565-574 
5. Satpathy SK, Mohanty N, Nanda P and Samal G. 
Severe falciparum malaria. Indian J Pediatr 2004; 
71(2):133-135 
6. Barragan A, Klremsssner PG, Wahlgre M and 
Carlson J. Blood group A antigen is a co-receptor 
in Plasmodium falciparum rosetting. Infection 
and Immunity. 2000; 68:2971-2975. 
7. Pathirana SL, Alles HK, Bandara S, Phone-Kyaw 
M, Perera MK, Wickremasinghe AR, Mendis KN 
and Handunnetti SM. ABO-blood-group types 
and protection against severe, Plasmodium 
falciparum malaria. Ann Trop Med Parasitol 
2005; 99(2):119-124. 
8. Rowe JA,  Handel IA, Thera MA, Deans A-M, 
Lyke KE, Kone A, Diallo DA, Raza A, Kai O, 
Marsh M, Plowe CV, Doumbo OK and Mouldset 
JM. Blood group O protects against severe 
Plasmodium falciparum malaria through the 
mechanism of reduced resetting. PNAS 2007; 
104(44): 17471–17476. 
9. Fortin A, Stevenson MM and Gros P. 
Susceptibility to malaria as a complex trait: big 
pressure from a tiny creature. Hum Mol Genet 
2002; 11(20): 2469-2478. 
10. Min-Oo G, Gros P. Erythrocyte variants and the 
nature of their malaria protective effect. Cell 
Microbiol 2005; 7(6):753-763. 
11. Pasvol G. How many pathways for invasion of 
the red blood cell by the malaria parasite? Trends 
Parasitol 2003; 19(10): 430-432. 
12. Protopopoff N, Matowo J, Malima R, Kavishe R, 
Kaaya R, Wright A, West PA, Kleinschmidt I, 
Kisinza W, Mosha FW and Rowland M. High 
level of resistance in the mosquito Anopheles 
gambiae to pyrethroid insecticides and reduced 
susceptibility to bendiocarb in north-western 
Tanzania. Malar J 2013; 12:149. 
13. Ranson H, N'guessan R, Lines J, Moiroux N, 
Nkuni Z and Corbel V. Pyrethroid resistance in 
African anopheline mosquitoes: What are the 
implications for malaria control? Trends Parasitol 
2011; 27: 91–98. 
14. Wongsrichanalai C, Barcus MJ, Muth S, 
Sutamihardja A and Wernsdorfer WH. A review 
of malaria diagnostic tools: microscopy and rapid 
diagnostic test (RDT). Am J Trop Med Hyg 
2007; 77(6 Suppl): 119-127. 
15. Kwiatkowski DP.  How malaria has affected the 
human genome and what human genetics can 
teach us about malaria. Am J Hum Genet 2005; 
77: 171–190.  
16. Schwartz E. Prophylaxis of malaria. Mediterr J 
Hematol Infect Dis 2012; 4(1): e201245 
17. Nosten F, White NJ. Artemisinin-based 
combination treatment of falciparum malaria. Am 
J Trop Med Hyg 2007; 77(Suppl 6): 181–192. 
 
Asian Pac. J. Health Sci., 2016; 3 (4):34-43                                    e-ISSN: 2349-0659, p-ISSN: 2350-0964 
_____________________________________________________________________________________________________________________________________  
 _______________________________________________________________________________________________________________________________________ 
Nwachukwu et al                      ASIAN PACIFIC JOURNAL OF HEALTH SCIENCES, 2016;3(4):34-43 
www.apjhs.com      41 
 
18. Goldberg DE, Siliciano RF and Jacobs Jr WR. 
Outwitting evolution: Fighting drug resistance in 
the treatment of TB, malaria and HIV. Nat Inst of 
Health: Cell. 2012; 148(6): 1271–1283. 
19. Neuberger A, Zhong K, Kain KC, and Schwartz 
E. Lack of evidence for chloroquine resistant 
Plasmodium falciparum malaria, Leogane, Haiti. 
Emerging Infectious Diseases 2012; 18(9): 1487-
1489 
20. Center for Disease Control (CDC). Infectious 
diseases related to travel: Malaria. Traveler’s 
Health Yellow Book. Chapter 3. 2016 Available 
athttp://wwwnc.cdc.gov/travel/yellowbook/2016/i
nfectious-diseases-related-to-travel/malaria (15 
August 2016). 
21. Black F, Bygbjerg I, Effersoe P, Gomme G, 
Jepsen S and Jensen GA. Fansidar resistant 
falciparum malaria acquired in South East Asia. 
Trans R Society of Trop Mede and Hyg 1981; 
75(5): 715-716. 
22. Vleugels MP, Wetsteyn JC and Meuwissen JH. 
Fansidar-resistant Plasmodium falciparum 
infection from Tanzania. Trop Geogr Med 1982; 
34(3): 263-265. 
23. Farooq U, Mahajan RC. Drug resistance in 
malaria. J Vect Borne Dis 2004; 41: 45–53. 
24. Lell B, Kremsner PG. Clindamycin as an 
antimalarial drug: Review of clinical trials. 
Antimicrob Agents Chemother 2002; 46(8): 
2315–2320;  
25. Gaillard T, Madamet M and Pradines B. 
Tetracyclines in malaria. Malar J 2015; 14: 445. 
 
26. Cosgriff TM, Boudreau EF, Pamplin CL, 
Doberstryn EB and Desjardins RE. Evaluation of 
antimalarial activity of the phenanthrene 
methanol halofantrine. Am J Trop Med Hyg 
1982; 31:1075–1079. 
27. CDC. entre for Disease Control (2015) Treatment 
of Malaria: Guidelines for Clinicians. Part 2: 
General Approach to Treatment and Treatment of 
Uncomplicated Malaria. June 10, 2015. 
http://www.cdc.gov/malaria/diagnosis_treatment/
clinicians2.html  (15 August 2016) 
28. Nanyunja M, Orem JN,  Kato F,  Kaggwa M, 
Katureebe C, and Saweka J. Malaria treatment 
policy change and implementation: The case of 
Uganda. Malaria Research and Treatment. 
Volume 2011, Article ID 683167, 14 pages.  
29. Cui L, Su X-Z. Discovery, mechanisms of action 
and combination therapy of artemisinin. Nat Inst 
of Health: Expert Rev Anti Infect Ther 2009; 
7(8): 999–1013. 
30. Dondorp AM, Nosten F, Yi P, Das D, Phae Phyo 
A, Tarning J, Lwin KM, Ariey F, Hanpithakpong 
W, Lee SJ, Ringwald P, Silamut K, Imwong M, 
Chotivanich K, Lim P, Herdman T, An SS, 
Yeung S, Singhasivanon P, Day NPJ, D.M., 
Lindegardh N, Socheat D, M.D., and White NJ. 
Artemisinin resistance in Plasmodium falciparum 
malaria. N Engl J Med 2009; 361: 455-467;  
31. WHO (2016) Malaria Q&A on artemisinin 
resistance. Media Centre, Programmes. 16 July 
2016.http://www.who.int/malaria/media/artemisi
nin_resistance_qa/en/ (15 August 2016) 
32. Maggini S, Wintergerst ES, Beveridge S and 
Hornig DH. Selected vitamins and trace elements 
support immune function by strengthening 
epithelial barriers and cellular and humoral 
immune responses. Br J Nutr 2007; 98(Suppl 1): 
S29-S35 
33. Nyakeriga AM, Troye-Blomberg M, Chemtai 
AK, Marsh K and Williams TN. Malaria and 
nutritional status in children living on the coast of 
Kenya. Am J Clin Nutr. 2004; 80: 1604–1610. 
34. Calis JC, Phiri KS, Faragher EB, Brabin BJ, 
Bates I, Cuevas LE, de Haan RJ, Phiri AI, 
Malange P, Khoka M, Hulshof PJ, van Lieshout 
L, Beld MG, Teo YY, Rockett KA, Richardson 
A, Kwiatkowski DP, Molyneux ME and van 
Hensbroek MB: Severe anemia in Malawian 
children. NEJM 2008; 358: 888-899.  
35. Davis TM, Binh TQ, Danh PT, Dyer JR, St John 
A, Garcia-Webb P and Anh TK. Serum vitamin A 
and E concentrations in acute falciparum malaria:  
modulators or markers of severity? Clin Sci 
(Lond) 1994; 87: 505-511. 
36. Galan P, Samba C, Luzeau R and Amedee-
Manesme O. Vitamin A deficiency in pre-school 
age Congolese children during malarial attacks. 
Part 2: Impact of parasitic disease on vitamin A 
status. International Journal for Vitamin and 
Nutrition Research Internationale Zeitschrift fur 
Vitamin- und Ernahrungsforschung 1990; 60: 
224-228.  
37. Shankar AH, Prasad AS. Zinc and immune 
function: The biological basis of altered 
resistance to infection. Am J Clin Nutr 1998; 68: 
447S–463S.  
38. Tabone MD, Muanza K, Lyagoubi M, Jardel C, 
Pied S, Amedee-Manesme O, Grau GE and 
Mazier D. The role of interleukin-6 in vitamin A 
deficiency during Plasmodium falciparum 
malaria and possible consequences for vitamin A 
supplementation. Immunology 1992; 75: 553-
554. 
 
Asian Pac. J. Health Sci., 2016; 3 (4):34-43                                    e-ISSN: 2349-0659, p-ISSN: 2350-0964 
_____________________________________________________________________________________________________________________________________  
 _______________________________________________________________________________________________________________________________________ 
Nwachukwu et al                      ASIAN PACIFIC JOURNAL OF HEALTH SCIENCES, 2016;3(4):34-43 
www.apjhs.com      42 
 
39. Semba R. The role of vitamin A and related 
retinoids in immune function. Nutr Rev 1998; 56: 
S38-S48. 
40. Ross AC, Gardner EM. The function of vitamin 
A in cellular growth and differentiation, and its 
roles during pregnancy and lactation. Adv Exp 
Med Biol 1994; 40 352:187-200. 
41. Serghides L, Kain KC. Mechanism of protection 
induced by vitamin A in falciparum malaria. 
Lancet 2002; 359: 1404-1406. 
42. Shankar AH, Genton B, Semba RD, Baisor M, 
Paino J, Tamja S, Adiguma T, Wu L, Rare L, 
Tielsch JM, Alpers MP and West KP Jr. Effect of 
vitamin A supplementation on morbidity due to 
Plasmodium falciparum in young children in 
Papua New Guinea: A randomised trial. Lancet 
1999; 354(9174): 203-209.  
43. Cusick SE, Tielsch JM, Ramsan M, Jape JK, 
Sazawal S, Black RE and Stoltzfus RJ. Short-
term effects of vitamin A and antimalarial 
treatment on erythropoiesis in severely anemic 
Zanzibari preschool children. Am J Clin Nutr 
2005; 82(2): 406-412. 
44. Binka F, Ross D and Morris S. Vitamin A 
supplementation and childhood malaria in 
northern Ghana. Am J Clin Nutr 1995; 61: 853-
859. 
45. Olofin, IO, Spiegelman D, Aboud S, MD, 
Duggan C, Danaei G and Fawzi WW.  
Supplementation with multivitamins and vitamin 
A and incidence of malaria among HIV-Infected  
Tanzanian Women. J Acquir Immune Defic 
Syndr 2014; 67: S173–S178. 
46. Zeba AN, Sorgho H, Rouamba N, Zongo I, 
Rouamba J, Guiguemde RT, Hamer DH, Mokhtar 
N and Ouedraogo JB. Major reduction of malaria 
morbidity with combined vitamin A and zinc 
supplementation in young children in Burkina 
Faso: A randomized double blind trial. Nutrition J 
2008; 7:7 
47. Mwanga-Amunpaire J, Ndeezi G and Tumwine 
JK. Effect of vitamin A adjunct therapy for 
cerebral malaria in children admitted to Mulago 
hospital: A randomized controlled trial. African 
Health Sciences 2012; 12(2): 90 – 97. 
48. Frey R, Uresky S. Vitamin B complex. Gale 
Encyclopedia of Alternative Medicine 
Encyclopedia.com 2005; http://www.encyclo 
pedia.com/doc/1G2-3435100812.html (14 August 
2016). 
49. Krishna S, Taylor AM, Supanaranond W, et al. 
Thiamine deficiency and malaria in adults from 
southeast Asia. Lancet 1999; 353: 546–549. 
50. Adamolekun B, Eniola A. Thiamine-responsive 
acute cerebellar ataxia following febrile illness. 
Central Afr J Med 1993; 39:40–1 
51. Müller IB, Wrenger C. Vitamin metabolism in 
the malaria parasite. Encyclopedia of Malaria 31 
May 2014, pp 1-7 44;   
52. Müller IB, Hyde JE, Wrenger C. Vitamin B 
metabolism in Plasmodium falciparum as a 
source of drug targets. Trends Parasitol 2010; 
26(1): 35-43. 
53. Thurnham DI, Oppenheimer SJ and Bull R. 
Riboflavin status and malaria in infants in Papua 
New Guinea. Trans R Soc Trop Med Hyg 1983; 
77: 423–424. 
54. Das BS, Das DB, Satpathy RB, Patnaik JK and 
Bose TK. Riboflavin deficiency and severity of 
malaria. Eur J Clin Nutr 1988; 42: 277–283. 
55. Barraviera B, Machado PE and Meira DA. 
Glutathione reductase activity and its relation 
with riboflavin levels measured by 
methemoglobin reduction by cystamine in 
patients with malaria (preliminary report). Rev 
Inst Med Trop Sao Paulo 1988; 30:107–108. 
56. Anderson BB, Giuberti M, Perry GM, Salsini G, 
Casadio I, Vullo C. Low red blood cell 
glutathione reductase and pyridoxine phosphate 
oxidase activities not related to dietary riboflavin: 
selection by malaria? Am J Clin Nutr 1993; 57: 
666–672. 
57. Dutta P. Enhanced uptake and metabolism of 
riboflavin in erythrocytes infected with 
Plasmodium falciparum. J Protozool 1991; 38: 
479–83 
58. Akompong T, Ghori N and Haldar K. In vitro 
activity of riboflavin against the human malaria 
parasite Plasmodium falciparum. Antimicrob 
Agents Chemother 2000; 44:88–96. 
59. Adumanya OC, Uwakwe AA, Odeghe OB, 
Essien EB and Okere TO. Assessment of the 
potency of some selected anti-malaria drugs on 
the supplements of B2 and orange fruit juice 
(combination therapy) African Journal of 
Biochemistry Research 2012; 6 (14): 179-184.  
60. WHO. Nutrition Guideline: Optimal serum and 
red blood cell folate concentrations in women of 
reproductive age for prevention of neural tube 
defects. Geneva: World Health Organization; 
2015 pp 1-44.  
61. Muller IB Hyde JE. Antimalaria drugs: Modes of 
action and mechanisms of parasite resistance. 
Future Microbiology 2010; 5(12): 1857-1873. 
62. Hamilton PJ, Gebbie DA, Wilks NE and Lothe F. 
The role of malaria, folic acid deficiency and 
haemoglobin AS in pregnancy at Mulago 
 
Asian Pac. J. Health Sci., 2016; 3 (4):34-43                                    e-ISSN: 2349-0659, p-ISSN: 2350-0964 
_____________________________________________________________________________________________________________________________________  
 _______________________________________________________________________________________________________________________________________ 
Nwachukwu et al                      ASIAN PACIFIC JOURNAL OF HEALTH SCIENCES, 2016;3(4):34-43 
www.apjhs.com      43 
 
Hospital. Trans R Soc Trop Med Hyg 1972; 66: 
594–602. 
63. Fleming AF, Werblinska B. Anaemia in 
childhood in the quinea savanna of Nigeria. Ann 
Trop Paediatr 1982; 2:161–173. 
64. Carter JY, Loolpapit MP, Lema OE et al. 
Reduction of the efficacy of antifolate 
antimalarial therapy by folic acid 
supplementation. Am J Trop Med Hyg 2005; 73: 
166–170.  
65. van Hensbroek MB, Morris-Jones S, Meisner S et 
al. Iron, but not folic acid, combined with 
effective antimalarial promotes haematological 
recovery in African children after acute 
falciparum malaria. Trans R Soc Trop Med Hyg 
1995; 89: 672–676. 
66. Watkins WM, Mberu EK, Winstanley PA et al. 
The efficacy of antifolate antimalarial 
combination in Africa: A predictive model based 
on pharmacodynamic and pharmacokinetic 
analyses. Parasitol Today 1997; 13: 459–464. 
67. Wintergerst ES, Maggini S and Hornig DH. 
Immune enhancing role of vitamin C and zinc 
and effect on clinical conditions. Ann Nutr Met 
2006; 50: 85–94. 
68. Marva E, Golenser J, Cohen A, Kitrossky N, Har-
El R and Chevion M. The effects of ascorbate-
induced free radicals on Plasmodium falciparum. 
Trop Med Parasitol 1992; 43:17–23. 
69. Mohammad A. Effect of serum antioxidant 
ascorbic acid concentration by malarial infection. 
Man. The Experiment 2012; 3(4): 214-215.  
70.  D’Souza V, D’Souza B. Comparative study on 
lipid peroxidation and antioxidant vitamins E and 
C in falciparum and vivax malaria. Indian J Clin 
Biochem 2006; 21(2):103–106. 
71. Winter RW, Ignatushchenko M, Ogundahunsi 
OA, Cornell KA, Oduola AM, Hinrichs DJ and 
Riscoe MK. Potentiation of an antimalarial 
oxidant drug. Antimicrob Agents Chemother 
1997; 41(7):1449–1454. 
72. Mahajan SS, Kamath VR and Ghatpande SS. 
Synergistic antimalarial activity of ketones with 
rufigallol and vitamin C. Parasitol 2005; 131: 
459–466. 
73. Iyawe HOT, Onigbinde AO, and Aina OO. Effect 
of chloroquine and ascorbic acid interaction on 
the oxidative stress status of Plasmodium berghei 
infected mice. Int J Pharmacol 2006; 2(1):1–4 
74. Ganiyu K.A, Akinleye M.O and Fola T.  A study 
of the effect of ascorbic acid on the 
antiplasmodial activity of Artemether in 
Plasmodium berghei infected mice. Journal of 
Applied Pharmaceutical Science 20012; 2(6): 96-
100. 
75. St John A, Davis TM, Binh TQ, Thu LT, Dyer JR 
and Anh TK. Mineral homoeostasis in acute renal 
failure complicating severe falciparum malaria. J 
Clin Endocrinol Metab 1995; 80: 2761-2767. 
76. Davis TM, Pukrittayakamee S, Woodhead JS, 
Holloway P, Chaivisuth B and White NJ Calcium 
and phosphate metabolism in acute falciparum 
malaria. Clin Sci (Lond)1991;  81: 297-304. 
77. Lương KVQ, Nguyễn LTH. The role of Vitamin 
D in malaria. J Infect Dev Ctries 2015; 9(1): 8-
19. 
78. He X, Yan J, Zhu X, Wang Q, Wei P, et al. 
Vitamin D inhibits the occurrence of 
experimental cerebral malaria in mice by 
suppressing the host inflammatory response. J 
Immunol 2014; 193(3): 1314-1323. 
79. Cusick SE, Opoka RO, Lund TC, John CC and 
Polgreen LE. Vitamin D Insufficiency Is 
Common in Ugandan Children and Is Associated 
with Severe Malaria. PLoS ONE 2014;  9(12): 
e113185 
80. Madden K, Feldman HA, Smith EM, Gordon 
CM, Keisling SM, Sullivan RM, Hollis BW, 
Agan AA and Randolph AG.Vitamin D 
deficiency in critically ill children. Pediatrics 
2012; 130(3): 421–428.  
81. Levander OA, Ager AL, Morris VC and May 
RG. Qinghaosu, dietary vitamin E, selenium and 
cod-liver oil: Effect on the susceptibility of mice 
to the malarial parasite Plasmodium yoellii. Am J 
Clin Nutr 1989; M: 346-352. 
82. Davis TME, Binh DTQ, Danh PT, Dyer JR, St 
John A, Garcia-Webb P and ANH TK.  Serum 
vitamin A and E concentrations in acute 
falciparum malaria: Modulators or markers of 
severity? Clinical Science 1994; 87: 505-511. 
83. Davis TME, Garcia-Webb P, Lin-Chun Fu, 
Spencer JL, Beilby J and Xing-B G. Antioxidant 
vitamins in acute malaria. Trans R SOC Trop 
Med Hyg 1993; 87: 596-597. 
84. Awodele O, Emeka PM, Akintonwa A and Aina 
OO. Antagonistic effect of vitamin E on the 
efficacy of artesunate against Plasmodium 
berghei infection in mice.  African Journal of 
Biomedical Research 2007; 10: 51 – 57. 
Source of Support: Nil  
Conflict of Interest: None  
 
